Since their introduction in the mid- to late 1990s, anti-TNF-α agents have remained among the most widely used immunosuppressive therapies in IBD and across the spectrum of IMIDs, owing to their broad anti-inflammatory effects and well-established clinical efficacy. Here, TNF is linked to inflammatory bowel disease.